Google
Trusted Resources: News & Events
Latest announcements and gatherings
ASH launches sickle cell disease clinical trials network to accelerate therapy development
ASH launched a clinical trials network designed to accelerate development of novel therapies for patients with sickle cell disease.
The network will match clinical trial sponsors with research sites, facilitate patient recruitment and provide consulting services. A core component will be a centralized data repository developed and maintained by ASH.
“We are on the brink of a new era in sickle cell disease research and treatment. Interest in this disease is expanding, with more than 40 treatments and more than a dozen devices in the research and development pipeline,” ASH President Alexis A. Thompson, MD, MPH, professor of pediatrics in the division of hematology, oncology and stem cell transplantation at Northwestern Medicine and associate director of equity and minority health at Ann and Robert H. Lurie Children’s Hospital of Chicago, said in a press release.
+myBinderRelated Content
-
Dexmedetomidine as an adjuvant to analgesic strategy during vaso-occlusive episodes in adolescents with sickle cell ...Sickle cell disease (SCD)-patients exper...
-
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
Scientists edit genome to cure sickle cell anemiahttps://www.youtube.com/watch?v=4LKzM3G6...
-
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCDThe Green Park Collaborative (GPC) is wo...
-
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease TherapiesThe American Society of Hematology (ASH)...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.